Pfizer announced a voluntary recall of one lot of Premarin (conjugated estrogens) 1.25mg tablets due to an incorrect expiration date applied to the bottle label.  

The affected product has Lot #M35953S and NDC 0046-1104-91. The expiration as stated on the bottle label is 11/17 and the product is supplied in 1,000-count bottles. 

Related Articles

Premarin, an estrogen product, is indicated for moderate to severe vasomotor symptoms of menopause; moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; postmenopausal osteoporosis prevention (consider alternative treatments); hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. It is also indicated to treat breast cancer (for palliation only) in appropriately selected women and men with metastatic disease and to treat advanced androgen-dependent carcinoma of the prostate (for palliation only).

Premarin is also supplied as 0.3mg, 0.45mg, 0.625mg, and 0.9mg strength tablets. Anyone with the recalled lot in inventory should stop distribution immediately and return to Stericycle , Inc. The Company noted that the potential risk to patients is considered negligible.

For more information call (800) 805-3093 or visit